120 related articles for article (PubMed ID: 3738914)
1. Serum neuron-specific enolase as a marker useful for monitoring the effectiveness of therapy in patients with neuroblastoma--as compared with urinary catecholamine metabolites.
Hashimoto K; Gotoh Y; Tada K
Tohoku J Exp Med; 1986 May; 149(1):25-30. PubMed ID: 3738914
[TBL] [Abstract][Full Text] [Related]
2. Serial determination of serum neuron-specific enolase in patients with neuroblastoma and other pediatric tumors.
Tsuchida Y; Honna T; Iwanaka T; Saeki M; Taguchi N; Kaneko T; Koide R; Tsunematsu Y; Shimizu K; Makino S
J Pediatr Surg; 1987 May; 22(5):419-24. PubMed ID: 3585664
[TBL] [Abstract][Full Text] [Related]
3. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course.
Zeltzer PM; Marangos PJ; Evans AE; Schneider SL
Cancer; 1986 Mar; 57(6):1230-4. PubMed ID: 3002599
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
Zhang H; He X; Miao Q; Li L; Song J; Jiang X
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
[TBL] [Abstract][Full Text] [Related]
5. Hormonal activity may predict aggressive behavior in neuroblastoma.
Zambrano E; Reyes-Múgica M
Pediatr Dev Pathol; 2002; 5(2):190-9. PubMed ID: 11910515
[TBL] [Abstract][Full Text] [Related]
6. Age dependence and prognostic impact of neuron specific enolase (NSE) in children with neuroblastoma.
Berthold F; Engelhardt-Fahrner U; Schneider A; Schumacher R; Zieschang J
In Vivo; 1991; 5(3):245-7. PubMed ID: 1893081
[TBL] [Abstract][Full Text] [Related]
7. Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients.
Verly IR; van Kuilenburg AB; Abeling NG; Goorden SM; Fiocco M; Vaz FM; van Noesel MM; Zwaan CM; Kaspers GL; Merks JH; Caron HN; Tytgat GA
Eur J Cancer; 2017 Feb; 72():235-243. PubMed ID: 28061374
[TBL] [Abstract][Full Text] [Related]
8. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group.
Zeltzer PM; Marangos PJ; Parma AM; Sather H; Dalton A; Hammond D; Siegel SE; Seeger RC
Lancet; 1983 Aug; 2(8346):361-3. PubMed ID: 6135871
[TBL] [Abstract][Full Text] [Related]
9. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
10. High levels of immunoreactive nervous system-specific enolase in sera of patients with neuroblastoma.
Ishiguro Y; Kato K; Shimizu A; Ito T; Nagaya M
Clin Chim Acta; 1982 May; 121(2):173-80. PubMed ID: 7046994
[TBL] [Abstract][Full Text] [Related]
11. Tumour markers are poor predictors for relapse or progression in neuroblastoma.
Simon T; Hero B; Hunneman DH; Berthold F
Eur J Cancer; 2003 Sep; 39(13):1899-903. PubMed ID: 12932669
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factor in neuroblastoma.
Evans AE; D'Angio GJ; Propert K; Anderson J; Hann HW
Cancer; 1987 Jun; 59(11):1853-9. PubMed ID: 3567848
[TBL] [Abstract][Full Text] [Related]
13. Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma.
Berthold F; Hunneman DH; Harms D; Käser H; Zieschang J
Eur J Cancer; 1992; 28A(12):1950-4. PubMed ID: 1419287
[TBL] [Abstract][Full Text] [Related]
14. Neuron-specific enolase evaluation in patients with neuroblastoma.
Massaron S; Seregni E; Luksch R; Casanova M; Botti C; Ferrari L; Martinetti A; Molteni SN; Bellani FF; Bombardieri E
Tumour Biol; 1998; 19(4):261-8. PubMed ID: 9679736
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients.
Strenger V; Kerbl R; Dornbusch HJ; Ladenstein R; Ambros PF; Ambros IM; Urban C
Pediatr Blood Cancer; 2007 May; 48(5):504-9. PubMed ID: 16732582
[TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of methylated catecholamine metabolites in a child with neuroblastoma maturing into ganglioneuroma.
Candito M; Soler C; Deville A; Bekri S; Chambon P; Thyss A
Med Pediatr Oncol; 1996 Jan; 26(1):57-60. PubMed ID: 7494513
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of combined serum CA125, NSE and 24-hour urine VMA for the prediction of recurrence in children with neuroblastoma.
Li J; Qi Z; Chen M; Wang J; Liu X
Ital J Pediatr; 2023 Aug; 49(1):102. PubMed ID: 37620978
[TBL] [Abstract][Full Text] [Related]
18. Serum neuron-specific enolase in children's cancer.
Cooper EH; Pritchard J; Bailey CC; Ninane J
Br J Cancer; 1987 Jul; 56(1):65-7. PubMed ID: 3476145
[TBL] [Abstract][Full Text] [Related]
19. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: comparison with 24-hour urine collections.
Tuchman M; Morris CL; Ramnaraine ML; Bowers LD; Krivit W
Pediatrics; 1985 Feb; 75(2):324-8. PubMed ID: 3969335
[TBL] [Abstract][Full Text] [Related]
20. Enolase isozymes as markers for differential diagnosis of neuroblastoma, rhabdomyosarcoma, and Wilms' tumor.
Ishiguro Y; Kato K; Ito T; Horisawa M; Nagaya M
Gan; 1984 Jan; 75(1):53-60. PubMed ID: 6327451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
